Review
Oncology
Prachi Mishra, Dipranjan Laha, Robert Grant, Naris Nilubol
Summary: This article reviews current treatment practices for thyroid cancer and emphasizes on novel targeted molecular therapy. With rapidly expanding knowledge of the molecular biology and increased availability of genetic testing, exciting paradigm shifts in treatment strategies have been observed. Targeted therapies and personalized treatments have become a trend with the development of new treatment strategies, accelerating the advancement of treatments for thyroid cancer.
Review
Biochemistry & Molecular Biology
Lizhuo Zhang, Qingqing Feng, Jiafeng Wang, Zhuo Tan, Qinglin Li, Minghua Ge
Summary: Thyroid cancer is a common endocrine malignant tumor, and surgery, chemotherapy, radiotherapy, and radioactive iodine therapy are the standard treatment modalities. However, multi-tyrosine kinase inhibitors and immune checkpoint inhibitors in combination with tyrosine kinase inhibitors have emerged as novel therapies for controlling the progression of thyroid cancer. This article discusses the molecular basis of thyroid cancer, reviews targeted therapeutic drugs in clinical research, and explores potentially novel molecular therapeutic targets.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2023)
Article
Chemistry, Medicinal
Yujie Zhang, Zhichao Xing, Tianyou Liu, Minghai Tang, Li Mi, Jingqiang Zhu, Wenshuang Wu, Tao Wei
Summary: This review focuses on the rapid development of treatment for advanced thyroid cancer and the study of drug resistance mechanisms. The current treatment for advanced thyroid cancer is not satisfactory due to the existence of drug resistance. Understanding the mechanisms of drug resistance in thyroid cancer is crucial for improving the effectiveness of combination therapy and promoting the development of new drugs.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Review
Pharmacology & Pharmacy
Huafeng Jiang, Senjun Zhou, Gang Li
Summary: Colorectal cancer (CRC) is a common and lethal type of cancer, and early diagnosis and treatment can significantly improve survival chances. Recent advancements in molecular biology have led to the discovery of novel biomarkers for early diagnosis, including the gut microbiota as a potential biomarker for CRC screening and treatment. Treatment options for CRC include surgical resection, chemotherapy, immunotherapy, and targeted therapies such as tyrosine kinase inhibitors (TKIs). However, there is a knowledge gap when it comes to bringing tailored medicines into clinical practice.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Skye Montoya, Deborah Soong, Nina Nguyen, Maurizio Affer, Sailasya P. Munamarty, Justin Taylor
Summary: Development of targeted therapies has provided nonchemotherapeutic options for patients, with small molecule kinase inhibitors being a key focus. However, resistance to these therapies may develop, necessitating multiple lines of treatment. Combinations of therapies targeting complimentary pathways may be more effective in overcoming drug resistance.
Review
Biochemistry & Molecular Biology
Zhaozhao Wang, Shu Qu, Jiahao Yuan, Wen Tian, Jinglei Xu, Rui Tao, Shilong Sun, Tao Lu, Weifang Tang, Yong Zhu
Summary: This article reviews the biological function of spleen tyrosine kinase (SYK), its relationship with diseases, and therapies targeting SYK. It also proposes the development of new therapeutic approaches for targeting SYK using new technologies.
BIOORGANIC & MEDICINAL CHEMISTRY
(2023)
Review
Oncology
Qiuxiao Yu, Xuwen Zhang, Li Li, Chi Zhang, Jian Huang, Wenting Huang
Summary: Patients diagnosed with radioiodine refractory thyroid cancer (RAIR-TC) cannot undergo novel I-131 therapy due to reduced expression of sodium iodide symporter (NIS) and/or impairment of NIS trafficking. Identifying RAIR-TC patients and selecting proper treatment strategies remain challenging. This review focuses on the clinical scenarios and molecular alterations involved, providing insights for targeted therapies.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Maciej Ratajczak, Damian Gawel, Marlena Godlewska
Summary: Thyroid cancers are among the most common tumors of the endocrine system, with a constant rise in cases observed for decades. Early diagnosis and personalized therapies, such as kinase inhibitors, are crucial for effective treatment. Despite advancements in detection and treatment, targeted treatments are being developed to improve outcomes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Endocrinology & Metabolism
Christian Okafor, Julie Hogan, Margarita Raygada, Barbara J. Thomas, Srivandana Akshintala, John W. Glod, Jaydira Del Rivero
Summary: Medullary thyroid carcinoma is a rare neuroendocrine tumor linked to RET gene mutations. The development of new RET-targeting therapies provides effective options for treatment, but resistance remains a challenge.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Oncology
Maria Florencia Mercogliano, Sofia Bruni, Florencia Luciana Mauro, Roxana Schillaci
Summary: Breast cancer is a common and deadly disease, with HER2 overexpression being associated with a poor prognosis. While trastuzumab is the standard treatment, many patients do not respond to it. Other HER2-targeted therapies, such as pertuzumab, margetuximab, and T-DM1, as well as tyrosine kinase inhibitors, have been developed. Combination therapies with immune checkpoint inhibitors, CAR-T cells, CAR-NK cells, CAR-M cells, and vaccines are also being explored. This review discusses the different HER2-targeted therapies and potential combinations to overcome resistance.
Review
Oncology
Jeffrey W. Fuchs, Brian C. Schulte, Joseph R. Fuchs, Mark Agulnik
Summary: Soft tissue sarcomas are rare malignant tumors derived from mesenchymal cells, and their high morbidity and mortality are often associated with advanced and metastatic disease. Significant progress has been made in the use of targeted therapies for the treatment of soft tissue sarcoma over the past two decades. The ability to study various cellular markers and pathways related to sarcomagenesis has led to the development and approval of multiple novel therapies.
FRONTIERS IN ONCOLOGY
(2023)
Review
Biology
Md Lutful Kabir, Feng Wang, Andrew H. A. Clayton
Summary: Cancer is a major global cause of death, and the development of anti-cancer drugs is crucial for combating this disease. However, current drugs face challenges such as side-effects and disease resistance. Spectroscopic methods, particularly fluorescence, can provide important information on drug-target and drug-non-target interactions. Understanding the intrinsic fluorescence of drugs can aid in the development of future drugs with improved side-effects and reduced disease resistance.
Review
Oncology
Maria San Roman-Gil, Javier Pozas, Diana Rosero-Rodriguez, Jesus Chamorro-Perez, Alvaro Ruiz-Granados, Ignacio Ruz Caracuel, Enrique Grande, Javier Molina-Cerrillo, Teresa Alonso-Gordoa
Summary: Thyroid cancer is a common endocrine malignancy with increasing incidence. Recent advances in understanding the molecular mechanisms of thyroid cancer have improved treatment approaches. Selective RET inhibitors have shown promising results in selected patients, but resistance mechanisms have been observed. This review provides an analysis of resistance mechanisms to RET inhibitors, aiming to inform the development of next-generation therapies and combination strategies.
CANCER TREATMENT REVIEWS
(2022)
Review
Oncology
Benoit Pilmis, Yousra Kherabi, Pauline Huriez, Jean-Ralph Zahar, Djamel Mokart
Summary: Targeted therapies have revolutionized cancer management, but they come with numerous infectious complications. This review highlights the main infectious complications associated with different targeted therapies and emphasizes the importance of identifying at-risk patients and implementing appropriate strategies to prevent or treat these complications.
Review
Oncology
Tomohiro Enokida, Makoto Tahara
Summary: Anti-VEGFR therapy is crucial in treating thyroid cancer but can lead to dangerous adverse reactions. To minimize risks, physicians need to understand the characteristics of these reactions and take appropriate measures. The development of multitarget tyrosine kinase inhibitors has improved prognosis, but effective management of related adverse events is essential.